SCHEMBL13865843

SCHEMBL13865843

Cc1cccc(-c2nc3c(C)cccc3nc2C)c1F

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ RAB9A P51151 2/20 0.51
▸ MAPT P10636 1/20 0.51
▸ MAPK1 P28482 1/20 0.51
▸ PIM1 P11309 9/20 0.40
▸ PIM2 Q9P1W9 9/20 0.40
▸ ATM Q13315 1/20 0.38
▸ MGAM O43451 1/20 0.37
▸ GAA P10253 1/20 0.37
▸ SI P14410 1/20 0.37
▸ MGAM2 Q2M2H8 1/20 0.37
▸ ADORA2A P29274 1/20 0.36
▸ MBNL1 Q9NR56 1/20 0.36
▸ NPC1 O15118 1/20 0.35
▸ ALDH1A1 P00352 1/20 0.35
▸ HPGD P15428 1/20 0.35
▸ HTT P42858 1/20 0.35
▸ SMN1; SMN2 Q16637 1/20 0.35
▸ NPSR1 Q6W5P4 1/20 0.35
▸ ELANE P08246 1/20 0.33
▸ PDE2A O00408 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13865857 0.84 RAB9A (0.49) RAB9AMAPTMAPK1ATMMGAM
SCHEMBL8802391 0.75 MAPT (0.51) RAB9AMAPTMAPK1PIM1PIM2
SCHEMBL8604288 0.74 MAPT (0.52) RAB9AMAPTMAPK1GAANPC1
SCHEMBL16934069 0.74 ACHE (0.46) RAB9AATMMGAMGAASI
SCHEMBL20475325 0.72 RAB9A (0.53) RAB9AMAPTMAPK1GAANPC1
SCHEMBL31643056 0.72 RAB9A (0.53) RAB9AMAPTMAPK1GAANPC1
SCHEMBL13865841 0.70 MGAM (0.52) RAB9AMAPTMAPK1ATMMGAM
SCHEMBL17035490 0.68 ACHE (0.46) RAB9AMGAMGAASIMGAM2
SCHEMBL14764415 0.68 MAPT (0.44) RAB9AMAPTMAPK1PIM1PIM2
SCHEMBL12578244 0.67 MAPT (0.58) RAB9AMAPTMAPK1GAAALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090137597-A1 Novel quinoxalinone derivatives MSD K.K. (JP) 2009-05-28 — — US disclosed
US-7388010-B2 Quinoxalinone derivatives BANYU PHARMACEUTICAL CO., LTD. (JP) 2008-06-17 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090137597-A1 Novel quinoxalinone derivatives NDUFB1, NDUFB6, NDUFB7 RAB9A 1059/4885MAPT 4476/4885MAPK1 786/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback